PDCD1 and colorectal cancer: Combination approaches incorporating both PD1/PDL1 and CTLA4 blockade, have seen clinical approval in mismatch-repair deficient colorectal cancer, renal cell carcinoma, and hepatocellular carcinoma (17–19).